Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Angelicin is a naturally occurring organic compound classified as an angular furanocoumarin. It is found in various plants such as those from the Apiaceae and Fabaceae families and can also be referred to as isopsoralen. Angelicin acts primarily as a photosensitizer; upon exposure to long-wave ultraviolet (UV) light (as in PUVA therapy), it forms monoadducts with DNA by binding to pyrimidine bases. This photobinding inhibits DNA replication and nucleic acid synthesis in target cells. Angelicin has been studied for its potential use in photochemotherapy for skin disorders like psoriasis and vitiligo and has shown anti-tumor activity by inhibiting tumor cell growth. Additionally, angelicin exhibits anti-inflammatory effects through inhibition of NF-κB and MAPK signaling pathways; it also demonstrates antiviral properties and can inhibit monoamine oxidase (MAO) activity in vitro[1][3][4]. Despite these activities, angelicin itself is less commonly used clinically than related compounds such as psoralen.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on angelicin.